SHORT COMMUNICATION

Chemokine (C-X-C Motif) Receptor 4 Regulates Lung Endothelial Barrier Permeability During Resuscitation from Hemorrhagic Shock

F. S. BABU1, H. M. LAPORTE1, S. P. NASSOY1, M. MAJETSCHAK2,3

1Department of Surgery, Burn and Shock Trauma Research Institute, Loyola University Chicago, Stritch School of Medicine, Maywood, IL, USA, 2Department of Surgery, University of South Florida Morsani College of Medicine, Tampa, FL, USA, 3Department of Molecular Pharmacology and Physiology, University of South Florida Morsani College of Medicine, Tampa, FL, USA

Received December 18, 2018
Accepted April 4, 2019
Epub Ahead of Print June 6, 2019

Summary
Chemokine (C-X-C motif) receptor 4 (CXCR4) agonists have been shown to protect lung endothelial barrier function in vitro. In vivo effects of CXCR4 modulation on lung endothelial permeability are unknown. Here we tested the effects of the CXCR4 agonist ubiquitin and the antagonist AMD3100 on lung vascular permeability and cytokine concentrations in a rat hemorrhage model. Animals were hemorrhaged (mean arterial blood pressure 30 mmHg for 30 min), treated with vehicle, ubiquitin (0.7 and 3.5 μmol/kg) or AMD3100 (3.5 μmol/kg), and resuscitated with crystalloids. Evans blue extravasation was employed to quantify lung vascular permeability. Ubiquitin dose-dependently reduced Evans blue extravasation into the lung. AMD3100 increased Evans blue extravasation. With AMD3100, TNFα levels in lung homogenates were increased; while TNFα levels were lower with ubiquitin, these differences did not reach statistical significance. Our findings suggest that CXCR4 regulates lung vascular permeability and further point towards CXCR4 as a drug target to confer lung protection during resuscitation from traumatic-hemorrhagic shock.

Key words
CXCR4 • Ubiquitin • AMD3100 • Endothelial permeability • Lung

Corresponding author
M. Majetschak, Department of Surgery, Morsani College of Medicine, University of South Florida, 12901 Bruce B Downs Blvd., MDC 3127, Tampa, Florida 33612, USA. E-mail: majetschak@health.usf.edu

Development of acute respiratory distress syndrome (ARDS) remains a major contributor to morbidity and mortality in critically ill trauma patients (Blank and Napolitano 2011, Ranieri et al. 2012, Dushianthan et al. 2011, Gonzales et al. 2015). While impairment of pulmonary endothelial barrier function in response to local and systemic coagulation and inflammation is considered the hallmark in the development of ARDS, the underlying pathophysiology is not well defined. Therapeutic strategies to protect lung endothelial barrier function during the early inflammatory response to traumatic-hemorrhagic shock and to reduce the risk of ARDS development are not available. Such strategies, however, would be desirable as they have the potential to improve survival and reduce morbidity in trauma patients. Several lines of pre-clinical evidence suggest that activation of chemokine (C-X-C motif) receptor 4 (CXCR4) confers lung protection in various models of lung injury and ARDS (Majetschak et al. 2004, Garcia-Covarrubias et al. 2008, Guo et al. 2016, Baker et al. 2012, Nassoiy et al. 2018). Furthermore, the natural CXCR4 agonists (C-X-C motif) chemokine ligand 12 (CXCL12) and ubiquitin, and CTCE-0214, a synthetic CXCL12 analogue, have previously been shown to attenuate thrombin-induced impairment of lung endothelial barrier function in vitro (Kobayashi et al. 2014, Guo et al. 2016, Cheng et al. 2017). Whether pharmacological modulation of CXCR4 influences lung endothelial barrier function in vivo, however, is unknown.
Thus, we tested whether pharmacological activation or blockade of CXCR4 affects lung endothelial barrier function during the inflammatory response to hemorrhagic shock and resuscitation in a rat model. We utilized Evans blue extravasation to quantify in vivo lung vascular permeability as the primary study endpoint. All procedures were performed according to National Institutes of Health Guidelines for Use of Laboratory Animals and approved by the Institutional Animal Care and Use Committee. Male Sprague Dawley rats (300-350 g) were purchased from Harlan (Indianapolis, IN, USA). Anesthetized (isoflurane inhalation) animals were oro-tracheally intubated with a 16-gauge EXEL disposable safelet angiocatheter (EXELINT International, Los Angeles, CA, USA) and mechanically ventilated with a SomnoSuite small animal anesthesia system (Kent Scientific Corporation, Torrington, CT, USA). Animals were ventilated with an initial positive end expiratory pressure (PEEP) of 2 mmHg, a fraction of inspired oxygen (FiO2) of 1.0 and anesthetized with 2.5 % isoflurane. Tidal volumes were titrated to maintain normal PaCO2 (35-45 mmHg). The femoral artery was then cannulated with a 24-gauge BD angiocath shielded IV catheter (Becton, Dickinson and Company, Franklin Lakes, NJ, USA) to allow for monitoring of arterial blood pressure and blood withdrawal. The femoral vein was cannulated with 1.5-french tubing for fluid and drug administration. After instrumentation and recording of baseline parameters, animals were hemorrhaged to mean arterial blood pressure (MAP) of 30 mmHg for 30 min. In series 1, vehicle (1.1 ml normal saline (NS), n=5), 0.7 (n=5) or 3.5 (n=5) μmol/kg ubiquitin in 1.1 ml NS were injected intravenously at t=30 min. In series 2, 1.1 ml vehicle (n=6) or 3.5 μmol/kg AMD3100 (n=5) in 1.1 ml NS were injected intravenously at t=30 min. In both series, drugs were administered randomized and blinded. Immediately after drug administration, animals were resuscitated with 1.5-times of their blood volume of warmed NS from t=30 min to t=55 min. At t=90 min, 0.5 % Evans blue solution in phosphate buffered saline

![Fig. 1. Effects of pharmacological CXCR4 modulation on lung vascular permeability after hemorrhagic shock and fluid resuscitation. Animals were hemorrhaged to a mean arterial blood pressure (MAP) of 30 mmHg, followed by standardized fluid resuscitation. Arrows show time points of drug administration. A/B: Open symbols: vehicle. Grey symbols: Ubiquitin 0.7 μmol/kg. Black symbols: Ubiquitin 3.5 μmol/kg. Data are mean ± standard deviation. A. Hemorrhage volume (ml/kg). B. Squares: MAP (mm Hg). Circles: Resuscitation fluid (ml). C. Evans Blue concentrations in lung homogenates from animals in A/B. Data are expressed as % of vehicle treated animals. Boxes extend from the 25th-75th percentiles; horizontal lines show the median; whiskers indicate minimum/maximum. Statistically significant differences are indicated. D/E: Open symbols: vehicle. Black symbols: AMD3100 3.5 μmol/kg. Data are mean ± standard deviation. D. Hemorrhage volume (ml/kg). E. Squares: MAP (mmHg). Circles: Resuscitation fluid (ml). Significant differences in MAP between groups are indicated. F. Evans blue concentrations in lung homogenates from animals in D/E. Data are expressed as % of vehicle treated animals. Boxes extend from the 25th-75th percentiles; horizontal lines show the median; whiskers indicate minimum/maximum. Statistically significant differences are indicated.](image-url)
(25 mg/kg) were administered intravenously. At t=120 min, a bilateral thoracotomy was performed, and the rats were exsanguinated. The right ventricle was isolated from the systemic circulation and the pulmonary artery was cannulated and flushed with 20 ml of phosphate buffered saline until clear effluent drained from the femoral arterial catheter. Bilateral bronchoalveolar lavage (BAL) was performed and lung specimens were harvested. Tissue samples were weighed, homogenized in formamide (1.5 weight/volume) and centrifuged (16000 g, 15 min, 4°C); the supernatant was collected, and absorbance was measured at 610 nm in a microplate reader. Cytokine concentrations (interleukin (IL)-6, IL-10, tumor necrosis factor (TNFα) in tissue homogenates were measured using the DuoSet ELISA Development kit (R&D Systems), as recommended by the manufacturer. Protein concentrations were measured with the Bio-Rad DC Protein Assay kit. Arterial blood gases and routine laboratory parameters were analyzed using the Element point of care veterinary blood gas, electrolyte and critical care analyzer (Cuattro Veterinary USA, Loveland, CO, USA). Data were analyzed with 1-way or 2-way ANOVA with Bonferroni’s multiple comparisons test or Student’s t-test, as appropriate. A 2-tailed p<0.05 was considered significant. All data analyses were performed with the GraphPad Prism 7 program. Data are described as mean ± standard deviation.

There were no differences in any physiological parameters among groups at baseline. Hemorrhage volumes (Fig. 1A), MAP and volumes of resuscitation fluids (Fig. 1B) were comparable among animals in series 1. With 0.7 μmol/kg ubiquitin, Evans blue concentrations in lung homogenates were 97±16 % (p>0.05 vs. vehicle), and with 3.5 μmol/kg ubiquitin 72±16 % of vehicle treated animals (100±15 %, p< 0.05) (Fig. 1C). These observations are in line with the previously described effects of ubiquitin on tissue wet/dry weight ratios in a porcine polytrauma model with direct lung injury and in a rat unilateral lung ischemia-reperfusion injury model (Baker et al. 2012, García-Covarrubias et al. 2008). Furthermore, our observation that ubiquitin treatment reduces Evans blue extravasation into the lung compares well with the protective effects of the CXCR4 agonists ubiquitin and CXCL12 on thrombin-induced impairment of lung endothelial barrier function in vitro (Cheng et al. 2017). To assess the role of the endogenous CXCR4 agonists in the regulation of lung endothelial barrier function during resuscitation from hemorrhagic shock, we then performed series 2 and compared the effects of the CXCR4 antagonist.
AMD3100 with vehicle treatment. AMD3100 was administered in a dose equimolar to the dose of ubiquitin that reduced Evans blue extravasation in series 1. While hemorrhage volumes were comparable between groups (Fig. 1D) and volumes of resuscitation fluid volumes were indistinguishable between the vehicle and the AMD3100 groups, MAP was significantly lower with AMD3100 treatment from t=60-120 min (Fig. 1E). This observation is consistent with the effects of AMD3100 on blood pressures and fluid requirements that have been described previously in other rat and pig trauma-hemorrhage models (Bach et al. 2016, Bach et al. 2014).

As compared with vehicle-treated animals, Evans blue concentrations in lung homogenates were significantly increased with AMD3100 treatment (100±11 % vs. 125±23 %, p<0.05). Our findings that ubiquitin and AMD3100 have diametrically opposing effects on Evans blue extravasation into the lung compare well with the observations that AMD3100 treatment exerts effects opposite to the effects of ubiquitin in trauma models and neutralizes the effects of ubiquitin when co-administered in equimolar concentrations (Bach et al. 2012, Bach et al. 2016, Bach et al. 2014). The previous finding that AMD3100 does not affect human pulmonary endothelial cell monolayer barrier function in vitro is not contradictory because these experiments were performed in the absence of endogenous CXCR4 agonists (Cheng et al. 2017). Thus, the results of the present study suggest that endogenous CXCR4 agonists have lung protective functions and that treatment with such agonists further improves lung endothelial barrier function in vivo.

In both series, blood gases, plasma electrolyte and lactate concentrations and protein concentrations in BAL fluids were comparable among groups (p>0.05 for all parameters, not shown). Our findings that blood gases were within the normal range in all animals and that BAL protein concentrations were low (<0.3 mg/ml in all groups) were anticipated because of the short observation period in the present study, which does not permit the development of ARDS or significant protein leakage into the alveolar space.

To assess whether pharmacological CXCR4 modulation also affects inflammation markers in the lung parenchyma, we measured TNFα, IL-6 and IL-10 as prototypical pro- and anti-inflammatory inflammation markers in extracts from lungs after removal of blood from the lung vasculature. While there were no statistically significant differences among groups for IL-6 and IL-10 concentrations per mg total protein in lung homogenates (Fig. 2A/B), TNFα concentrations per mg total protein were significantly increased with AMD3100 treatment, as compared with vehicle and ubiquitin treatment (Fig. 2C). While TNFα levels were lower with ubiquitin treatment, these differences did not reach statistical significance in post-hoc testing. Nevertheless, it appears worthwhile mentioning that the degree by which ubiquitin treatment reduced Evans blue extravasation and TNFα levels in lung homogenates was comparable with the degree by which AMD3100 exerted opposite effects. Furthermore, the findings from the present study confirm previous findings in other trauma models, which indicated that CXCR4 activation reduces inflammation markers that are generally considered as pro-inflammatory (Garcia-Covarrubias et al. 2008, Bach et al. 2012).

In conclusion, in the present study, we provide initial evidence that CXCR4 activation reduces, whereas CXCR4 blockade enhances in vivo lung vascular permeability during resuscitation from hemorrhagic shock. While the blood pressure lowering effects of AMD3100 are consistent with previous observations in other hemorrhage and resuscitation models, it remains to be determined whether these effects are caused by reduced intravascular volumes due to impaired endothelial barrier function with subsequent third spacing of fluids, by direct effects on vascular smooth muscle function or by a combination of both (Bach et al. 2014). In vivo experiments to delineate the underlying mechanisms, however, are beyond the scope of the present study. Nevertheless, our findings demonstrate that in vitro effects of CXCR4 modulation on lung endothelial barrier function can be translated in vivo (Cheng et al. 2017) and further suggest CXCR4 as a drug target to provide lung protection during the inflammatory response to trauma, hemorrhage and fluid resuscitation (Nassoity et al. 2018).

Conflict of Interest
There is no conflict of interest.

Acknowledgements
This research has been presented in part at the 41st Annual Conference on Shock, Scottsdale, Arizona, USA, June 2018. This work was supported by the Office of the Assistant Secretary of Defense for Health Affairs through the Peer Reviewed Medical Research Program under Award No. W81XWH-15-1-0262 and by the National Institute of General Medical Sciences (Awards R01GM107495 and T32GM008750). The content is solely the responsibility of the authors.
References


